



Annual Report and Audited Financial Statements for the year ended 30 June 2024



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Contents	Page
General Information	3
Investment Manager's Report	4
Directors' Report	6
Independent Auditor's Report	8
Custodian's Report	11
Supplementary Information	12
Portfolio Statement	13
Statement of Financial Position	14
Statement of Comprehensive Income	15
Statement of Cash Flows	16
Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares	17
Notes to the Financial Statements	18



Annual Report and Audited Financial Statements for the year ended 30 June 2024

General Information

Address and Registered Office

PO Box 255

Trafalgar Court, Les Banques St Peter Port, Guernsey

GY1 30L

Channel Islands

Investment Manager

Momentum Global Investment Management Limited

The Rex Building 62 Queen Street

London EC4R 1EB

United Kingdom

Distribution Partner

Fintax Consulting Group (Pty) Ltd

No. 2 Seventh Avenue

Parktown North

2193

South Africa

Manager

Momentum Wealth International Limited

La Plaiderie House

La Plaiderie

St Peter Port, Guernsey

GY1 1WF

Channel Islands

Sub-Investment Manager

Morningstar Investment Management South Africa

Limited

5th Floor

20 Vineyard Road

Claremont

7708

South Africa

Directors of the Incorporated Cell

Robert Alastair Rhodes

Roxanne Power

Marie Curutchet

Ray Mhere

Andrew Hardy (appointed 15 December 2023)

Ferdinand van Heerden (resigned 1 December 2023)

Administrator, Registrar & Secretary

Northern Trust International Fund Administration

Services (Guernsey) Limited

PO Box 255

Trafalgar Court

Les Banques

St Peter Port, Guernsey

GY1 3QL

Channel Islands

Legal Advisor

Carey Olsen

Carey House

Les Banques

St Peter Port, Guernsey

GY1 4BZ

Channel Islands

Independent Auditor

Ernst & Young LLP

PO Box 9

Royal Chambers

St Julian's Avenue

St Peter Port, Guernsey

GY1 4AF

Channel Islands

Custodian

Northern Trust (Guernsey) Limited

PO Box 71

Trafalgar Court

Les Banques

St Peter Port, Guernsey

GY13DA

Channel Islands



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Investment Manager's Report

Full year performance

The fund returned +12.1% over the past year (1 July 2023 to 30 June 2024).

Performance measured against benchmark

The fund's performance over the period lagged the benchmark return of +14.0%. However, the fund ended ahead of the peer group average return of +9.5% over the same period.

Benchmark: 65% MSCI All Country World Index and 35% Bloomberg Global Aggregate USD hedged. The benchmark is unchanged since the previous financial year end.

Peer group: Morningstar EAA Fund USD Moderate Allocation. The peer group is unchanged since the previous financial year end.

Significant events or trends impacting performance in the financial year

Global equity markets continued their strong run despite persistent inflation and a delay in the expected interest rate-cutting cycle over the past year. Central banks continue to keep a close eye on economic conditions, as sticky inflation has pushed expectations for the first rate cut out to later in 2024. Broadly, the global economy is in good shape, with strong job markets and a continued decline in inflation leading most market forecasters to pencil in rate cuts towards the end of 2024. Election risk remains, with the world's largest economy going to the polls in November this year; all eyes will be on whether it will result in a market-friendly outcome. The market remained data-driven, with shifts in sentiment around economic releases impacting performance on a monthly basis, particularly when pointing to a delay in interest rate cuts. While performance was volatile, markets generally moved higher over the period, with strong gains in certain regions.

Turning to equity markets, the hype surrounding artificial intelligence continued this year, driving stocks that may benefit from growth and disruption higher. These "Magnificent Seven" companies produced strong returns and largely increased concentration in most broader market indices. This led to a strong return from the US, and in particular the NASDAQ, as large US technology companies delivered strong returns. Notable performances included AI-related Nvidia (+191.5%), Apple (+9.1%), Meta (+75.9%), Alphabet (+52.2%), and Microsoft (+32.2%). Other regional equity markets, including Europe, the UK, and Germany, also produced strong returns, contributing positively to the fund's performance over the period. Additionally, strong performance from the fund's exposure to World Financials, World Communications Services, and US Healthcare added to overall performance. On the other hand, concerns about economic growth, deflation, and ongoing problems in the property sector led to souring sentiment towards China, making it the largest detractor from an equity perspective over the past year.

Fixed Income had a mixed performance over the past year. Expected interest rate cuts were tapered back further, pushing yields up (and prices down), particularly at the long end of the curve. Spread assets such as High Yield and Global Investment Grade Credit contributed positively to returns due to their higher-yielding nature and the current environment, which led to strong relative performance over the year. Longer-duration assets, such as US Treasuries, detracted from performance as the market pushed expected interest rate cuts further out. However, given the higher starting yield on short-duration assets, we saw positive performance over the past year. Emerging Markets Local Currency Debt also struggled as divergent central bank policies between Emerging Market central banks and Developed Market central banks led to a continued weakening of EM currencies against the US dollar over the year.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Investment Manager's Report (continued)

Portfolio Update

Over the year, Value (Dodge & Cox Worldwide US Stock) underperformed growth (Natixis Loomis Sayles US Eq Leaders) as large tech dominated returns. Sectors such as Healthcare (iShares S&P 500 Health Care Sector) and Consumer Staples (SPDR® S&P US Consumer Staples) produced a positive return but lagged the broader market. The hype around artificial intelligence continued to be a positive for sectors like Technology and Communication Services (Xtrackers MSCI World Comm Services), which acted as a tailwind to performance.

The Emerging Market fund managers (Fidelity Emerging Markets and Lazard Emerging Markets Equity) were able to navigate a very tricky year to produce a positive return. This was in the face of weakness in the larger index constituents including Brazil and China, which dragged down the Emerging Market basket. The weakness in China was pronounced and was the largest detractor from the equity mix over the past year (Baillie Gifford China).

Treasuries produced a mixed performance over the year. State Street Global Treasury was a leading contributor to performance over the year producing a positive return. On the other hand, the longer duration position detracted from performance as yields in the US ticked higher over the period (SPDR® Blmbrg 10+ Yr US Trs Bd ETF).

Risks

The strong run by the "Magnificent Seven" and the continued market concentration represents a risk to financial markets, as these companies are priced for extreme growth. Should we see results not reaching these growth targets, there is a risk of the market being especially punitive to these companies. Turning to macro risks, the market will likely be data-driven, with sentiment shifting in response to key economic releases as market participants continue to gauge if efforts from the major central banks to reduce inflation while avoiding a recession were successful. Going forward, uncertainty around inflation and interest rates will likely be front of mind for investors. Geo-political tensions are always difficult to measure and forecast, but any unexpected increase in geo-political tensions — whether via trade wars or actual wars — will likely hurt investment sentiment, lead to higher inflation, and cause further volatility in risk assets. Lastly, concerns around election risks remain, with the world's largest economy heading to the polls in November and a significant change in leadership occurring around the world, including in the UK.

Looking ahead

Pencilling an outlook for 2025 is particularly difficult in this environment. Going forward, market participants face an interesting period that requires careful longer-term positioning. While positive returns are always welcome, risk management plays an important role. With technology and Al-related sentiment continuing to run hot, inflationary pressures still vexing, elections in full swing, and a still-combustible atmosphere in the Middle East, it remains pivotal to balance the risk and return drivers in portfolios. We will continue to follow our valuation-driven approach by allocating assets to the most attractive areas of the market from a reward-for-risk perspective and ensure we build robust portfolios.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Directors' Report

The Directors present their annual report together with the audited financial statements of Fintax International Balanced Fund IC Limited (the "Incorporated Cell" or "Cell") for the year ended 30 June 2024.

Principal activities

The Cell with company number 47770 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company"). The activities and objectives of the Cell can be found in note 1 on page 18.

Going concern

The Directors have made an assessment of going concern including consideration of geo-political issues on the Cell. Refer to note 2 for the detailed disclosure.

Directors

The Directors of the Cell during the year and at the date of this report are set out on page 3.

Directors' interests

None of the Directors who held office during the year and at the date of this report had any disclosable interests in the shares of the Incorporated Cell.

Directors' responsibilities

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Incorporated Cell and of the profit or loss of the Incorporated Cell for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Incorporated Cell will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Incorporated Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020. They are also responsible for safeguarding the assets of the Incorporated Cell and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as each Director is aware, there is no relevant audit information of which the Incorporated Cell's auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Incorporated Cell's auditor is aware of that information.

The Board of Directors confirms that, throughout the period covered by the financial statements, the Cell complied with the Code of Corporate Governance issued by the Guernsey Financial Services Commission, to the extent it was applicable based upon its legal and operating structure and its nature, scale and complexity.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Directors' Report (continued)

Directors' responsibilities (continued)

The annual report together with the audited financial statements of the Incorporated Cell are published on the Manager's website. The Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website. The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent auditor

A rule was issued by the Independent Regulatory Auditors in South Africa (IRBA), which prescribed mandatory audit firm rotation. The Board of Momentum Group Limited ("MGL"), formerly Momentum Metropolitan Holdings Limited approved the appointment of a joint external auditor for the 2025 financial year. Shareholders of MGL will be informed of the new firm of external auditors once all regulatory approvals have been obtained. The change of external audit firm will be tabled for approval by the shareholders at the MGL's next annual general meeting.

As a subsidiary of MGL, the Directors of the Cell anticipate that Ernst & Young LLP will tender their resignation and the Directors will seek to appoint a new audit firm in line with the wider group.

Marie Curutchet Director

2 December 2024

Robert Rhodes
Director



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Independent Auditor's Report to the Members of Fintax International Balanced Fund IC Limited

Opinion

We have audited the financial statements of Fintax International Balanced Fund IC Limited (the "Incorporated Cell") for the year ended 30 June 2024 which comprise the Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares, and the related notes 1 to 16, including material accounting policy information. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- give a true and fair view of the state of the Incorporated Cell's affairs as at 30 June 2024 and of its profit for the year then ended:
- · have been properly prepared in accordance with International Financial Reporting Standards; and
- have been properly prepared in accordance with the requirements of The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Incorporated Cell in accordance with the ethical requirements that are relevant to our audit of the financial statements, including the UK FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Incorporated Cell's ability to continue as a going concern for the period to 31 December 2025.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Incorporated Cell's ability to continue as a going concern.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Independent Auditor's Report to the Members of Fintax International Balanced Fund IC Limited (continued)

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which The Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Incorporated Cell; or
- the financial statements are not in agreement with the Incorporated Cell's accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement set out on pages 6 and 7, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Incorporated Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Incorporated Cell or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

- We obtained an understanding of the legal and regulatory frameworks that are applicable to the Incorporated Cell and determined that the most significant are those that relate to the reporting framework (International Financial Reporting Standards, The Companies (Guernsey) Law, 2008 and the Protection of Investors (Bailiwick of Guernsey) Law, 2020);
- We understood how the Incorporated Cell is complying with those frameworks by making enquiries of management and
 those responsible for compliance matters and corroborated this by reviewing minutes of meetings of the Board of
 Directors and correspondence between the Incorporated Cell and the Guernsey Financial Services Commission. We
 gained an understanding of the Board's approach to governance, demonstrated by its review of compliance reports, the
 investment manager's reports and internal control processes;
- We assessed the susceptibility of the Incorporated Cell's financial statements to material misstatement, including how
 fraud might occur by considering the risk of management override and by identifying the valuation of investments
 (specifically manual price overrides) and the recognition of dividend income at year-end (cut-off) as fraud risks. We
 considered the controls the Incorporated Cell has established to address the risk identified by the directors or that
 otherwise seek to prevent, detect or deter fraud and how management and those charged with governance monitor
 those controls. We also considered the existence of any stakeholder influences which may cause management to seek to
 manipulate the financial performance and did not note any;



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Independent Auditor's Report to the Members of Fintax International Balanced Fund IC Limited (continued)

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud (continued)

Based on this understanding we designed our audit procedures to identify non-compliance with such laws and
regulations. Our procedures involved the review of minutes of meetings of the Board of Directors; review of compliance
reports; review of correspondence with the Guernsey Financial Services Commission; making inquiries of those charged
with governance; and performance of journal entry testing based on our risk assessment and understanding of the
business, with a focus on non-standard journals and those relating to areas with an identified associated fraud risk, as
described above.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the Incorporated Cell's members, as a body, in accordance with Section 262 of The Companies (Guernsey) Law 2008 and Paragraph 4.2(4) of the Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021. Our audit work has been undertaken so that we might state to the Incorporated Cell 's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Incorporated Cell and the Incorporated Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.

Signed by:

Enst Varill

4753914588A54C3...

Ernst & Young LLP Guernsey, Channel Islands Date: 06 December 2024



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Custodian's Report to the Members of Fintax International Balanced Fund IC Limited

Jersamad

In our opinion, the Cell has, in all material aspects, been managed for the year ended 30 June 2024 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules and Guidance 2021.

For and on behalf of

Northern Trust (Guernsey) Limited

2 December 2024



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Supplementary Information

		30.06.24	30.06.23
1.	NUMBER OF SHARES OUTSTANDING Class A	10,540,801	11,181,432
2.	NET ASSET VALUE PER SHARE - USD Class A	1.76	1.57
3.	HIGHEST/LOWEST PRICE - USD* Class A	1.76 / 1.48	1.58 / 1.33
4.	NUMBER OF SHARES SUBSCRIBED Class A	5,939	-
5.	NUMBER OF SHARES REDEEMED Class A	646,570	1,647,528

^{*}The highest/lowest price is based on prices from prior year end to current year end, being 30.06.2024.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Portfolio Statement

Portiono Statement			
	Holdings	Fair Value USD	% of Net Assets
Financial assets at fair value through profit or loss			
Collective Investment Schemes: 98.58% (2023: 95.24%)			
Alternative Investment Schemes Funds			
Colchester Local Markets Bond Fund	53,742	541,277	2.92
Total Alternative Investment Schemes Funds	•	541,277	2.92
Equity Funds			
Baillie Gifford China Fund - Class B Shares	84,907	438,338	2.36
Dodge & Cox Worldwide Funds - U.S. Stock Fund	27,906	1,302,630	7.02
Fidelity Funds - Emerging Markets Fund	35,156	558,983	3.01
iShares Core FTSE 100 UCITS ETF	3,653	722,679	3.90
iShares Core S&P 500 UCITS ETF USD Accu	3,606	2,092,995	11.29
iShares Edge MSCI USA Quality Factor UCITS ETF	93,021	1,324,619	7.14
iShares S&P 500 Health Care Sector UCITS ETF	49,613	570,301	3.08
Lazard Emerging Markets Equity Fund A Acc USD	577,274	735,678	3.97
Loomis Sayles U.S. Equity Leaders Fund	261,098	1,343,036	7.24
MSCI Europe Energy 35/20 Capped Index	1,202	269,629	1.45
Schroder European Fund - Class Z Accumulation GBP	227,636	464,725	2.51
SPDR MSCI World Financials UCITS ETF	5,831	370,327	2.00
SPDR S&P U.S. Consumer Staples Select Sector UCITS ETF	12,263	478,640	2.58
Vanguard FTSE Japan UCITS ETF	24,826	808,210	4.36
Xtrackers DAX UCITS ETF	2,960	544,722	2.94
Xtrackers MSCI World Communication Services UCITS ETF	13,186	303,805	1.64
Total Equity Funds		12,329,317	66.49
Fixed Income Funds			
Robeco Global Credits IBH USD	15,637	1,491,911	8.05
SPDR Bloomberg 10+ Year U.S. Treasury Bond UCITS ETF	29,043	645,481	3.48
State Street Global Treasury Bond Index Fund	70,795	930,291	5.02
Vanguard USD Treasury Bond UCITS ETF	85,237	2,156,283	11.62
Total Fixed Income Funds		5,223,966	28.17
Money Market Funds			
BlackRock ICS USD Liquidity Core Acc	1,098	184,544	1.00
Total Money Market Funds		184,544	1.00
Total Collective Investment Schemes		18,279,104	98.58
Financial assets at fair value through profit or loss		18,279,104	98.58
Other Net Assets: 1.42% (2023: 4.76%)		264,614	1.42
Net Assets Attributable To Holders Of Participating Redeemable Shares		18,543,718	100.00



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Statement of Financial Position

		As at	As at
	Notes	30.06.24 <u>USD</u>	30.06.23 <u>USD</u>
ASSETS	Motes	<u>03D</u>	<u>03D</u>
7.002.10			
CURRENT ASSETS			
Cash and cash equivalents	7	302,036	858,078
Financial assets at fair value through profit or loss	6	18,279,104	16,731,245
Interest receivable	3	102	1,295
Other receivables	8	332	304
Total assets	_	18,581,574	17,590,922
	_		
LIABILITIES			
CURRENT LIABILITIES			
Other payables	9	37,854	23,254
Liabilities (excluding net assets attributable to			
holders of participating redeemable shares)		37,854	23,254
Net assets attributable to holders of participating			
redeemable shares	3,11 _	18,543,718	17,567,666
Total liabilities	_	18,581,572	17,590,920
SHAREHOLDERS' EQUITY			
Management shares	10	2	2
Total equity	_	2	2
,	_		
Total equity and liabilities	=	18,581,574	17,590,922
Net asset value per participating redeemable share	11	1.76	1.57

The notes 1 to 16 on pages 18 to 32 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 2 December 2024 and signed on its behalf by:

Marie Curutchet

Director

Robert Rhodes Director



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Statement of Comprehensive Income

		Year ended ` 30.06.24	Year ended 30.06.23
	Notes	<u>USD</u>	<u>USD</u>
INCOME			
Net realised gains on financial assets at fair value through profit or loss	6	370,805	1,756,830
Change in unrealised gains/(losses) on financial assets at fair value through			
profit or loss	6	1,711,383	(322,065)
Net gains on financial assets at fair value through profit or loss		2,082,188	1,434,765
Deposit interest		12,256	13,436
Interest income		78,810	16,800
Dividend income		35,927	150,870
Net losses on forward derivative contracts		-	(82,186)
Other foreign exchange losses		(27,495)	(6,251)
Other gains Other gains	-	61	5,313
Total net income		2,181,747	1,532,747
OPERATING EXPENSES			
Audit fee		(12,898)	(8,780)
Custodian fee	13	(12,674)	(11,284)
Investment Management fee	13	-	(33,585)
Management and Administration fee	13	-	(26,875)
Management, Investment Management and Administration fee	13	(44,488)	(10,727)
Sub-Investment Management fee	13	(35,590)	(8,591)
Deposit interest		(1,632)	(318)
Directors' fee	13	(10,000)	(2,500)
Sundry expenses	-	(11,936)	(8,796)
Total operating expenses	-	(129,218)	(111,456)
Net profit for the year		2,052,529	1,421,291
Withholding tax			(5,155)
Increase in net assets attributable to holders of participating redeemable shares			
from operations	;	2,052,529	1,416,136

All items in the above statement derive from continuing operations. There is no difference between the increase in net assets attributable to holders of participating redeemable shares and comprehensive income.

The notes 1 to 16 on pages 18 to 32 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Statement of Cash Flows

	Year ended 30.06.24 <u>USD</u>	Year ended 30.06.23 <u>USD</u>
CASH FLOW FROM OPERATING ACTIVITIES		
Increase in net assets attributable to holders of participating redeemable	2.052.520	4 446 436
shares from operations	2,052,529	1,416,136
ADJUSTMENT FOR:	(0=0 00=)	(4 == 6 000)
Net realised gains on financial assets at fair value through profit or loss	(370,805)	(1,756,830)
Net change in unrealised (gains)/losses on financial assets at fair value	(4 = 44 000)	
through profit or loss	(1,711,383)	322,065
Net losses on forward derivative contracts	_	82,186
Effect of foreign exchange rate on cash	7,881	26,358
Dividend income	(35,927)	(150,870)
Deposit income	(12,256)	-
Interest income	(78,810)	-
Withholding tax	<u> </u>	5,155
Operating loss before working capital changes	(148,771)	(55,800)
Net decrease in other receivables	1,165	2,057
Net increase in other payables	14,600	1,864
Purchase of financial assets at fair value through profit or loss*	(1,915,328)	(22,699,198)
Sale of financial assets at fair value through profit or loss*	2,449,657	26,046,179
Net settlement of forward derivative contracts	-	(135,958)
Interest income received	78,810	-
Deposit interest received	12,256	_
Dividend received	35,927	145,715
Net cash generated from operating activities	528,316	3,304,859
CASH FLOW FROM FINANCING ACTIVITIES		
Cash received from issuance of participating redeemable shares	9,848	_
Cash paid on redemption of participating redeemable shares	(1,086,325)	(2,441,356)
Net cash used in financing activities	(1,086,323)	(2,441,356)
Net Cash used in infancing activities	(1,070,477)	(2,441,330)
Net (decrease)/increase in cash and cash equivalents	(548,161)	863,503
	858,078	
Cash and cash equivalents at the beginning of the year Effect of foreign exchange rate on cash	•	20,933
	(7,881)	(26,358)
Cash and cash equivalents at the end of the year	302,036	858,078

^{*} Purchases and sales of financial assets at fair value through profit or loss have been included as operating activity as this is the primary activity of the Cell.

The notes 1 to 16 on pages 18 to 32 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares

	Note	Year ended 30.06.24 <u>USD</u>	Year ended 30.06.23 <u>USD</u>
Net assets attributable to holders of participating redeemable			
shares at the beginning of the year		17,567,666	18,592,886
Proceeds from issuance of participating redeemable shares		9,848	-
Payments on redemption of participating redeemable shares Increase in net assets attributable to holders of		(1,086,325)	(2,441,356)
participating redeemable shares from operations		2,052,529	1,416,136
Net assets attributable to holders of participating redeemable			
shares at the end of the year	11	18,543,718	17,567,666

The notes 1 to 16 on pages 18 to 32 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

1. General information

The Fintax International Balanced Fund IC Limited (the "Incorporated Cell" or "Cell") with company number 47770, is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company").

The Cell's objective is achieving a balance of capital preservation and appreciation. A significant proportion of the portfolios will be held in the base currency. The portfolios will also invest into a wide range of other asset classes, including equities and property and so some degree of volatility is to be expected.

The Cell intends to achieve its investment objectives by investing globally, primarily via other collective investment schemes, in a wide range of asset classes including cash, bonds and equities. The Cell is suitable for investors with a time horizon of 3 to 5 years. The Cell may invest in the units of collective investment schemes which are also managed by the Investment Manager or an associate of the Investment Manager. The Cell may invest in forward foreign currency exchange contracts to reduce its currency exposure.

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager") with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager") and Morningstar Investment Management South Africa Limited (the "Sub-Investment Manager").

On 20 March 2024, amendments were made to the Supplemental Prospectus of the Cell which were as follows:

• The Company and the Cell have been approved for promotion in South Africa by the Financial Sector Conduct Authority (previously the Financial Services Board) of South Africa under section 65 of the Collective Investment Schemes Control Act 2002. Investors resident in the Republic of South Africa should read the schedule of Regulatory Similarities and Differences as set out under separate cover.

The financial statements were authorised for issue by the Board of Directors on 2 December 2024.

2. Material accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements.

2.1 Basis of preparation

The financial statements for the Incorporated Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards (IFRS). The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss (including derivative financial instruments).

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates, which are disclosed in note 4 of these Incorporated Cell's financial statements. It also requires the Board of Directors to exercise its judgement in the process of applying the Incorporated Cell's accounting policies.

Going concern

At the time of approving the financial statements, the Board has assessed redemption levels and there have been no significant redemptions. The Board has also considered the liquid nature of the investment portfolio, the absence of any borrowings or commitments and the economic viability of the Cell which is driven by its net asset value.

After careful consideration, the Board is satisfied that the Cell has sufficient liquidity to meet its liabilities for the period to 31 December 2025 and therefore it is appropriate to adopt the going concern basis in preparing the financial statements and they have a reasonable expectation that the Cell will continue in existence as a going concern.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

2. Material accounting policies (continued)

2.2 Adoption of new and revised accounting standards

The Directors have adopted a policy of applying new standards and interpretations when they become effective.

Standards, amendments and interpretations effective during the year

The following accounting standards, amendments and interpretations became effective for the first time in this reporting period:

Periods beginning on or after 1 January 2023:

- (a) IAS 8 Definition of Accounting Estimates Effective from 1 January 2023 Amendments regarding classification of liabilities and disclosure of accounting policies.
- (b) IAS 1 Disclosure Initiative Accounting Policies Effective from 1 January 2023 Amendments to help entities apply materiality judgements to accounting policy disclosure.

IAS 1 has been amended to replace the requirement for entities to disclose their significant accounting policies with a requirement to disclose material accounting policies. The policies presented in the financial statements for the year ended 30 June 2023 have been assessed, and those that are considered material have been disclosed for the year ended 30 June 2024.

The adoption of these standards has not had a material impact on the financial statements of the Incorporated Cell.

Standards, amendments and interpretations in issue not yet effective

A number of new standards, amendments and interpretations are effective for annual periods beginning on or after 1 January 2024 and have not been early adopted in preparing these financial statements. These include:

(a) IFRS S1 and IFRS S2 – Sustainability Disclosure Standards – Effective from 1 January 2024 – New standards regarding the disclosure of sustainability-related financial information.

The Board anticipates that the adoption of these standards, which will be adopted in the period which they become effective, will not have a material impact on the financial statements of the Cell.

2.3 Foreign currency translation

(a) Functional and presentation currency

The currency in which the financial information is shown in the financial statements of the Incorporated Cell is deemed to be its functional and presentational currency. In arriving at the functional currency, the Directors have considered the primary economic environment of the Incorporated Cell, and in doing so have considered the currency in which the original capital was raised, any distributions are to be made, performance is evaluated and ultimately, the currency in which capital would be returned on break up basis. They have also considered the currency to which the majority of the underlying investments are exposed and liquidity is managed. The Directors are of the opinion that the currency selected best represent the functional currency.

(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

2. Material accounting policies (continued)

2.4 Financial assets and financial liabilities at fair value through profit or loss

(a) Classification

The Incorporated Cell classifies its investments in Collective Investment Schemes, equities, and related derivatives as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are classified by the Board of Directors at fair value through profit or loss at inception. The Incorporated Cell does not classify any derivatives as hedges in a hedging relationship. Financial assets and financial liabilities are designated at fair value through profit or loss at inception, are managed, and their performance evaluated on a fair value basis in accordance with the Incorporated Cell's documented investment strategy. The Incorporated Cell's policies are for the Investment Manager and the Board of Directors to evaluate the information about these financial assets on a fair value basis together with other related financial information.

(b) Recognition/derecognition

Regular-way purchases and sales of investments are recognised on the trade date of the underlying security, so long as the underlying transaction has been confirmed by the relevant counterparty as at the Statement of Financial Position date. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Incorporated Cell has transferred substantially all risks and rewards of ownership.

(c) Measurement

Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed in the Statement of Comprehensive Income of the Incorporated Cell. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income in the period in which they arise.

(d) Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and trading securities) are based on quoted market prices at the close of trading on the reporting date. The Incorporated Cell adopted to utilise the last traded market price for both financial assets and financial liabilities where the last traded price falls within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the point within the bid-ask spread that is most representative of fair value. As a practical expedient to establish fair value within the bid-ask spread, management will use mid-market pricing. The market price used for assets which are not traded in active markets are those as supplied by their fund administrators.

2.5 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously. The Cell entered into a ISDA Master Netting Agreement with Northern Trust (Guernsey) Limited effective 17 June 2024.

2.6 Forward currency contracts

Forward foreign currency contracts are treated as derivative contracts and as such are recognised at fair value on the date on which they are entered into and subsequently remeasured at their fair value. Fair value is determined by rates in active currency markets. All derivatives are carried as assets when fair value is positive and as liabilities when fair value is negative. The gain or loss on remeasurement to fair value is recognised immediately through profit or loss in the Statement of Comprehensive Income within other losses and gains in the period in which they arise.

2.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

2. Material accounting policies (continued)

2.8 Other financial instruments

For other financial instruments, including amounts due to and from brokers and all receivables and payables, the carrying amounts as shown in the Statement of Financial Position approximate to fair value due to the short-term nature of these financial instruments.

2.9 Share capital

The Incorporated Cell has an authorised share capital of 100 management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

(a) Management shares

Management shares were issued to comply with the Guernsey Company Law, prior to its revision in 2008, under which there had to be a class of non-redeemable shares in issue in order that participating redeemable shares may be issued. The management shares are beneficially owned by the Manager, do not carry any right to dividends, are only entitled to vote at shareholder meetings where there are no participating redeemable shares in issue within the Incorporated Cell and are only entitled to return of capital on the winding up of the Incorporated Cell.

The Incorporated Cell has issued 2 management shares.

(b) Participating redeemable shares

The Incorporated Cell's capital is represented by participating redeemable shares with no par value, each carrying one vote, no matter which share class. Each share class carries identical rights, the only difference between the classes being either the management fee or the distribution partner fee which is charged to each class. These fees are disclosed in note 13.

The participating redeemable shares are redeemable at the holder's option and are classified as financial liabilities. Participating redeemable shares can be put back to the Incorporated Cell at any time for cash equal to a proportionate share of the Incorporated Cell's net asset value. The participating redeemable share is carried at the redemption amount that is payable at the Statement of Financial Position date if the holder exercises the right to put the share back to the Incorporated Cell.

All participating redeemable shares will rank equally for all dividends and other distributions, as adjusted to reflect any differences in the fees to which each class of participating redeemable share is subject. They are entitled to payment of a proportionate share based on the Cell's net asset value per share on the redemption date. The Cell has no restrictions or specific capital requirements on the subscriptions and redemptions of shares. The relevant movements are shown on the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares. In accordance with the Cell's investment objectives, and its risk management policies, the Cell endeavours to invest the subscriptions received in appropriate investments while maintaining sufficient liquidity to meet redemptions, such liquidity being augmented by short-term borrowings or disposal of listed securities where necessary.

To determine the net asset value of the Cell for subscriptions and redemptions, investments have been valued based on the last traded market prices as of the close of business on the relevant trading day.

2.10 Capital risk management

The fair value of the Cell's financial assets and financial liabilities approximate to its carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Incorporated Cell's objective when managing capital is to safeguard its ability to continue as a going concern in order to provide returns for shareholders. There are no externally imposed capital requirements on the Incorporated Cell. The Cell has no intention to borrow, other than to fund short-term liquidity requirements. The Incorporated Cell may arrange an overdraft facility for such purposes.

2.11 Interest and dividend income

Dividend income is recognised when the right to receive payment is established. All deposit interest and other income is accounted for on an accruals basis.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

2. Material accounting policies (continued)

2.12 Expenses

Expenses are accounted for on an accruals basis and all amounts have been allocated to the Statement of Comprehensive Income.

2.13 Custodian bank charges

Custodian bank charges include additional fees on top of the asking price of the security. The bid-asking spread is not disclosed as part of a custodian bank charge. This spread is included in the Statement of Comprehensive Income within the fair value net gain or loss.

2.14 Taxation

The Cell has been granted Exempt Status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,600 (2023: £1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are shown as a separate item in the Statement of Comprehensive Income.

3. Financial risk management

3.1 Strategy in using financial instruments

The Cell's activities and investment objectives expose it to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the Cell is exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place throughout the year.

The Cell's policies allow it to use derivative financial instruments to both moderate and create certain risk exposure.

3.2 Market price risk

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in Collective Investment Schemes. Through its investment in traded securities and instruments, the Cell is subject to market movements in the equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions are monitored by the Investment Manager and are reviewed by the Board of Directors.

The Cell's market price risk is managed through diversification of the investment portfolio by exposures to varying product categories, hence concentration of risk is minimised. At the year end, the financial assets at fair value through profit or loss which are subject to market price risk, are as follows:

As at 30 June	2024		2023	
	% of net			% of net
	Fair Value <u>USD</u>	assets	Fair Value <u>USD</u>	assets
Collective Investment Schemes	18,279,104	98.57	16,731,245	95.24
	18,279,104	98.57	16,731,245	95.24



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

3. Financial risk management (continued)

3.2 Market price risk (continued)

The Cell's market price risk is affected by three main components: changes in actual market prices, interest rate and foreign currency movements. Interest rate and foreign currency exchange rate movements are covered in notes 3.3 and 3.5, respectively. If the market indexes increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2024	2023
	Change in	Change in
	fair value	fair value
	<u>USD</u>	<u>USD</u>
Collective Investment Schemes	1,827,910	1,673,125
	1,827,910	1,673,125

3.3 Interest rate risk

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

The table below summarises the Cell's exposure to interest rate risks. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual re-pricing or maturity dates within one month.

As at 30 June	2024	2023
	<u>USD</u>	<u>USD</u>
Net financial assets on which no interest is paid	18,244,182	16,709,588
Net floating rate financial assets	302,036	858,078

Should interest rates have increased/decreased by 50 basis points with all other variables remaining constant, the increase/decrease in the net assets attributable to participating redeemable shareholders would amount to approximately:

As at 30 June	2024	2023
	<u>USD</u>	<u>USD</u>
Movement in net floating rate financial assets	1,510	4,290



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

3. Financial risk management (continued)

3.4 Cash flow risk

The Cell holds a significant amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.

3.5 Currency risk

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets, including investments denominated in currencies other than its functional currency, US Dollar, and therefore it is exposed to currency risk. The exposures are based on the currencies of the underlying assets in the Cell. Investments made via Collective Investment Funds are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risks:

As at 30 June	2024 <u>USD</u>	2023 <u>USD</u>
Net EUR exposure	271,684	2,076
Net GBP exposure	2,161,993	1,952,132
Net JPY exposure	174,225	352,731
Net SGD exposure	233	233
Net ZAR exposure	(913)	(913)

In accordance with the Cell's policies, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk. Such contracts are used on a regular basis.

Should the Cell's functional currency have strengthened or weakened by 5% against other currencies to which it is exposed and all other variables, including the price of all investments, had held constant, the net asset attributable to participating redeemable shareholders would have increased, or decreased, as follows:

As at 30 June	2024 <u>USD</u>	2023 <u>USD</u>
EUR exposure	13,584	104
GBP exposure	108,100	97,607
JPY exposure	8,711	17,637
SGD exposure	12	12
ZAR exposure	(46)	(46)

3.6 Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by the Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 3.2. No such redemption problems have been encountered.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

3. Financial risk management (continued)

3.6 Credit risk (continued)

All transactions in listed securities are settled/paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period, and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with its cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the Cell. The Northern Trust Company is a wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Government bonds held in the Cell's portfolio are Aaa and Aa2 rated by Moody's.

The Cell's maximum exposure to credit risk is the carrying value of the assets on its Statement of Financial Position.

3.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding their ability to process redemptions as normal.

The Cell has the ability to borrow to meet short-term liquidity requirements, however, to date, the Cell has not entered into such arrangements.

The table below analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the Statement of Financial Position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.

		Between		
	Less than 1	1 and 12	2024	2023
	month	months	Total	Total
	<u>USD</u>	<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss	18,279,104	-	18,279,104	16,731,245
Cash and cash equivalents	302,036	-	302,036	858,078
Deposit interest receivable	102	-	102	1,295
Other receivables	330	-	330	302
Other payables	(37,854)	-	(37,854)	(23,254)
Net assets attributable to participating redeemable				
shareholders	(18,543,718)	-	(18,543,718)	(17,567,666)
Net liquidity position	-	-	-	-

Participating redeemable shares are redeemed on demand at the holder's option. However, the Board of Directors does not envisage that the contractual maturity disclosed in the table above will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

3. Financial risk management (continued)

3.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The Cell's overall strategy remains unchanged.

The Cell has no externally imposed capital requirements.

3.9 Fair value disclosure

In the opinion of the Directors, there are no material differences between the net asset values of the underlying asset and fair values of the financial assets and liabilities.

4. Critical accounting estimates and judgements

The fair value of investments is considered to be the quoted, active market prices, or prices as supplied by the fund administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis. The Cell does not hold any Level 3 investments.

5. Portfolio analysis

The Cell's portfolios are organised by focusing on the type of security held, and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types which are disclosed in note 3.2 and the following main geographical areas:

	2024	2023
	<u>USD</u>	<u>USD</u>
Ireland	12,507,098	11,538,886
Luxembourg	3,525,907	3,056,128
United Kingdom	2,246,099	2,136,231
	18,279,104	16,731,245

The geographical segment for the portfolio is considered to be the country of incorporation of the financial assets.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

6. Financial assets at fair value through profit or loss

	2024	2023
	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss:		
Collective Investment Schemes	18,279,104	16,731,245
Total financial assets at fair value through profit or loss	18,279,104	16,731,245
Movement on financial assets at fair value through profit or loss		
Fair value of financial assets at the beginning of the year	16,731,245	18,446,305
Purchases of financial assets	1,915,328	22,699,198
Sales of financial assets	(2,449,657)	(25,849,023)
Realised gains on sales of financial assets	370,805	1,756,830
Movement in unrealised gains/(losses) on revaluation of financial assets	1,711,383	(322,065)
Fair value of financial assets at the end of the year	18,279,104	16,731,245
Comprising:		
Cost at the end of the year	16,005,804	16,169,328
Unrealised gains at the end of the year	2,273,300	561,917
	18,279,104	16,731,245

IFRS 13 requires the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety, is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Cell considers it to be the most advantageous market and would enter into transactions based on those prices.

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

6. Financial assets at fair value through profit or loss (continued)

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.

The following tables present the Cell's financial assets and financial liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2024 and 30 June 2023:

30 June 2024	Level 1	Level 2	Level 3	Total
	<u>USD</u>	<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss				
Collective Investment Schemes	18,279,104	-	-	18,279,104
	18,279,104	-	-	18,279,104
30 June 2023	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss	<u>03D</u>	<u>03D</u>	<u>03D</u>	<u>03D</u>
Collective Investment Schemes	16,731,245	-	-	16,731,245
	16,731,245	-	-	16,731,245

There were no movements or reclassifications of investments within the levels of the fair value hierarchy during the years ended 30 June 2024 and 30 June 2023.

The Cell's cash and cash equivalents and short-term receivables and payables are recorded at carrying value which approximates fair value.

7. Cash and cash equivalents

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	2024	2023
	<u>USD</u>	<u>USD</u>
Cash at bank	302,036	858,078
	302,036	858,078



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

8. Other receivables

	2024	2023
	<u>USD</u>	USD
Prepayments	330	302
Management shares receivable	2	2
	332	304
Other payables		

9.

	2024	2023
	<u>USD</u>	<u>USD</u>
Management, Investment Management and Administration fee payable	3,537	3,581
Sub-Investment Management fee payable	2,830	2,865
Custodian fee payable	701	1,512
Directors' fee payable	12,500	2,500
Audit fee payable	11,124	9,066
Sundry expense payable	7,162	3,730
	37,854	23,254

10. Share capital

The Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no-par value participating redeemable shares.

Management shares in issue	2024	2023
	<u>USD</u>	<u>USD</u>
Management shares	2	2

Participating redeemable shares in issue	Year ended 30 June 2024	Year ended 30 June 2023
Balance at the beginning of the year	11,181,432	12,828,960
Issue of participating redeemable shares	5,939	-
Redemption of participating redeemable shares	(646,570)	(1,647,528)
Balance at the end of the year	10,540,801	11,181,432

11. Net asset value per participating redeemable share

	NAV per share	Net assets attributable	Shares in issue	NAV per share	Net assets attributable	Shares in issue
As at 30 June	2024 <u>USD</u>	2024 <u>USD</u>	2024	2023 <u>USD</u>	2023 <u>USD</u>	2023
International Balanced Cell	1.76	18,543,718	10,540,801	1.57	17,567,666	11,181,432

12. Dividends payable to participating redeemable shareholders

No dividends were paid during the year (2023: Nil) and the Board does not intend to pay any dividends. All available income will be reinvested.

m

Fintax International Balanced Fund IC Limited

Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

13. Related party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

13.1 Management, Investment Management and Administration fee

The Cell is managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement, and the amended Supplemental Cell Prospectus dated 3 April 2023.

The Manager will be entitled to the payment of a fee of 0.25% of the NAV of the Cell per annum (subject to a minimum of USD25,000 per annum) (the "Management, Investment Management and Administration fee"). The Management fee will accrue as at each Valuation Point, based on the current valuation and is payable monthly in arrears. From the proceeds of the Management, Investment Management and Administration fee, the Manager shall settle the fees of the Administrator and the Investment Manager on behalf of the Cell.

Management, Investment Management and Administration fee charged during the year and accrued at year end:

	2024	2023
	<u>USD</u>	<u>USD</u>
Charged during the year	44,488	10,727
Accrued at year end	3,537	3,581

13.2 Management and Administration fee

Fee - % of NAV per annum

Up until 2 April 2023, the Manager was entitled to receive the following Management and Administration fee, chargeable on a sliding scale, payable monthly in arrears, based on the current valuation and subject to a minimum annual fee of USD22,000 or currency equivalent.

0.20%	Up to USD30m	
0.15%	Over USD30m	
Management and Administration fee charged in prior year and accrued at year end:		
	2024	2023
	<u>USD</u>	<u>USD</u>
Charged during the year		26,875
Accrued at year end	-	
Management fee rebate received during the year and accrued at year end:		
	2024	2023
	<u>USD</u>	<u>USD</u>
Received during the year	55	392
Accrued at year end		

Cell NAV



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

13. Related party transactions (continued)

13.3 Investment Management fee

The Manager has appointed an Investment Manager, Momentum Global Investment Management Limited, a UK registered company, to manage the investment portfolio of the Cell.

Up until 2 April 2023, the Investment Manager was entitled to receive a fee (the "Investment Management fee"), chargeable at a rate of 0.25% of the Cell's NAV per annum, which accrued as at each Valuation Point, based on the current valuation of the Cell, payable monthly in arrears. From 3 April 2023, the Investment Manager fee was settled by the Manager on behalf of the Cell.

Investment Management fee charged in prior year and accrued at year end:

	2024	2023
	<u>USD</u>	<u>USD</u>
Charged during the year		33,585
Accrued at year end		

13.4 Sub-Investment Management fee

On 3 April 2023, Morningstar Investment Management South Africa Limited was appointed Sub-Investment Manager. Pursuant to the terms of the Sub-Investment Management Agreement, the Sub-Investment Manager is entitled to a fee of 0.20% of the NAV of the Cell per annum (the "Sub-Investment Management fee") for the services rendered in connection with the Cell. The Sub-Investment Manager fee is accrued as at each Valuation Point, based on the current valuation of the Cell and is payable monthly in arrears.

Sub-Investment Management fee charged during the year and accrued at year end:

	2024	2023
	<u>USD</u>	<u>USD</u>
Charged during the year	35,590	8,591
Accrued at year end	2,830	2,865

13.5 Custodian fee

The Cell has engaged the services of Northern Trust (Guernsey) Limited to provide custodian services. The Custodian is entitled to the payment of a fee (the "Custodian fee") chargeable on a sliding scale in respect of all Share Classes, as follows, subject to a minimum of USD8,000 per annum.

Fee% of NAV		<u>Cell NAV</u>
0.05%	Up ·	to USD30m
0.04%	From USD30m to USD60m	
0.03%	From USD60m to USD100m	
0.02%	Ove	r USD100m
Custodian fee charged during the year and accrued at year end:		
	2024	2023
	<u>USD</u>	<u>USD</u>
Charged during the year	12,674	11,284
Accrued at year end	701	1,512



Annual Report and Audited Financial Statements for the year ended 30 June 2024

Notes to the Financial Statements

13. Related-party transactions (continued)

13.6 Distribution Partner fee

The Cell has appointed Fintax Consulting Group (Pty) Ltd as distribution partner to promote and market the Cell. On 3 April 2023, amendments were made to the Supplemental Cell Prospectus and effective from that date, the Distribution Partner has not been entitled to a fee. Previously since inception, the Distribution partner had waived their fee.

13.7 Board of Directors' remuneration

The Directors are entitled, effective from 3 April 2023, a fee of USD10,000 per annum (the "Directors' fee"). In addition, the Directors shall be entitled to be repaid for all reasonable out-of-pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of the Cell alone and not from the Cellular assets of other Cells of the Company or assets of the Company itself. The Directors' fees in respect of the Cell shall not exceed USD20,000 (or currency equivalent) in any twelve-month period.

Previously up until 2 April 2023, the Directors had waived their right to a fee.

Directors' fee charged during the year and accrued at year end:

	2024	2023
	<u>USD</u>	<u>USD</u>
Charged during the year	10,000	2,500
Accrued at year-end	12,500	2,500

14. Ultimate controlling party

In the opinion of the Directors, on the basis of the shareholding advised to them, the Cell has no ultimate controlling party.

15. Reconciliation of published valuation to financial statements

	2024	2023
	<u>USD</u>	<u>USD</u>
Net assets attributable to holders of participating redeemable shares per financial statements Adjustments:	18,543,718	17,567,666
Adjustment in value of assets at financial assets at fair value through profit and loss Adjustment in accruals Net assets attributable to the holders of participating redeemable shares per	879 1,794	(16,894)
published valuation	18,546,391	17,550,772
NAV per share per published valuation	1.76	1.57
NAV per share per financial statements	1.76	1.57

16. Subsequent events

These financial statements were approved for issuance by the Board on 2 December 2024. Subsequent events have been evaluated until this date.

No significant events have occurred in respect of the Cell that are considered material to the understanding of these audited financial statements.